RJ 4964
Alternative Names: RJ-4964Latest Information Update: 14 Sep 2023
At a glance
- Originator Nanjing Ruijie Pharma
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Idiopathic thrombocytopenic purpura
Most Recent Events
- 08 Aug 2023 Preclinical trials in Acute myeloid leukaemia in China (unspecified route) (Nanjing Ruijie Pharma pipeline, August 2023)
- 08 Aug 2023 Preclinical trials in Idiopathic thrombocytopenic purpura in China (unspecified route) (Nanjing Ruijie Pharma pipeline, August 2023)